Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HK-2 cell cultured with normal glucose, high glucose, dapagliflozin, metformin and vildagliptin

ABSTRACT: HK-2 cell cultured with normal glucose, high glucose, dapagliflozin, metformin and vildagliptin

PROVIDER: PRJNA742756 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

HK-2 cell cultured with normal glucose, high glucose, dapagliflozin, metformin and vildagliptin

Project description:To investigate the differential expressed circRNAs, and even their biological functions in human proximal tubular epithelial (HK-2) cells induced by normal glucose, high levels of glucose and treatment of dapagliflozin, metformin and vildagliptin.

2022-04-05 | GSE179226 | GEO

HK-2 cell cultured with normal glucose and high glucose

Project description:HK-2 cell cultured with normal glucose and high glucose

| PRJNA707218 | ENA

HK-2 cell cultured with normal glucose and high glucose

Project description:To investigate the differential expression of lncRNAs and mRNAs, and even their biological functions in human proximal tubular epithelial (HK-2) cells induced by either normal glucose or high levels of glucose. Keywords: Expression profiling by array

2022-04-05 | GSE158534 | GEO

SUDHL-4 cells: suspension vs. co-cultured with HK cells

Project description:We first performed miRNA analysis on SU-4 cells in suspension, and after 24 and 48 h of HK co-culture. To ensure that no HK cell contamination occurred, SU-4 cells in suspension and after co-culture were purified by CD19-positive magnetic selection, followed by total RNA isolation. Two-condition experiment, S4 vs. S4+HK cells. Biological replicates: 2 suspension controls, 2 co-cultured with HK cells, independently grown and harvested. One replicate per array.

2014-04-01 | E-GEOD-49253 | biostudies-arrayexpress

Transcriptomic data of MDA-MB-231 cells adapted to culture in media containing 0 mM or 2 mM metformin and cultured as mammospheres

Project description:We report the single-cell RNA sequencing data obtained from MDA-MB-231 breast cancer cells cultured in standard DMEM (high glucose) media, or adapted to culture in standard DMEM (high glucose) media containing 2 mM metformin, and then cultured as mammospheres

2020-10-23 | GSE110949 | GEO

Importance of AMPK in metformin suppression of liver glucose production

Project description:Metformin is now the most widely prescribed oral anti-diabetic agent worldwide, taken by over 150 million people annually. Although metformin has been used clinically to treat type 2 diabetes for over 60 years. Its mechanism of action remains only partially understood and controversial. In particular, this includes whether AMPK plays a role in metformin suppression of liver glucose production. To address this issue, we knocked out the AMPK catalytic alpha1 and alpha 2 subunits in the liver of HFD-fed adult homozygous mice. These mice were treated with a physiological relevent metformin dose (50 mg/kg/day) for 3 weeks. Liver samples were collected.

2019-11-13 | GSE114234 | GEO

RNAseq of C. elegans cultured on metformin sensitive and resistant E. coli strains with and without 50mM metformin treatment.

Project description:Metformin is the therapy of choice for treating type 2 diabetes and is currently repurposed for a wide range of diseases including aging. Recent evidence implicates the gut microbiota as a site of metformin action. Combining two tractable genetic models, the bacterium E. coli and the nematode C. elegans, we performed C. elegans RNAseq to investigate the role of the metformin sensitive OP50 and metformin resistant OP50-MR E. coli microbiota in the drug effects on the host. Our data suggest an evolutionarily conserved bacterial mediation of metformin effects on host lipid metabolism and lifespan.

2019-07-13 | E-MTAB-7272 | biostudies-arrayexpress

Metformin Impairs Intestinal Fructose Metabolism

Project description:Objective: To investigate the effects of metformin on intestinal carbohydrate metabolism in vivo. Method: Male mice preconditioned with a high-fat, high-sucrose diet were treated orally with metformin or a control solution for two weeks. Fructose metabolism, glucose production from fructose, and production of other fructose-derived metabolites were assessed using stably labeled fructose as a tracer. Results: Metformin treatment decreased intestinal glucose levels and reduced incorporation of fructose-derived metabolites into glucose. This was associated with decreased intestinal fructose metabolism as indicated by decreased enterocyte F1P levels and diminished labeling of fructose-derived metabolites. Metformin also reduced fructose delivery to the liver. Proteomic analysis revealed that metformin coordinately down-regulated proteins involved carbohydrate metabolism including those involved in fructolysis and glucose production within intestinal tissue. Conclusion: Metformin reduces intestinal fructose metabolism, and this is associated with broad-based changes in intestinal enzyme and protein levels involved in sugar metabolism indicating that metformin's effects on sugar metabolism are pleiotropic.

2024-04-27 | PXD041833 | JPOST Repository

Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin

Project description:Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear1. Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C-allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (p=6.6x10-14) greater metformin induced HbA1c reduction in 10,577 participants of European ancestry. rs8192675 is the top cis-eQTL for SLC2A2 in 1,226 human liver samples, suggesting a key role for hepatic GLUT2 in regulation of metformin action. In obese individuals C-allele homozygotes at rs8192675 had a 0.33% (3.6mmol/mol) greater absolute HbA1c reduction than T-allele homozygotes.This is about half the effect seen with the addition of a DPP-4 inhibitor, and equates to a dose difference of 550mg of metformin, suggesting rs8192675 as a potential biomarker for stratified medicine.

| EGAS00001001875 | EGA

SUDHL-4 cells: suspension vs. co-cultured with HK cells

2014-04-01 | GSE49253 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data